The OncoSil Medical share price is booming 66%. Here’s why

A man in a wheelchair stretches both arms into the air in success.A man in a wheelchair stretches both arms into the air in success.

Today is a good day for the OncoSil Medical Ltd (ASX: OSL) share price after the company released news of its pancreatic cancer treatment.

The treatment – which comes in the form of a device – has surpassed a major milestone. It has been used to treat a commercial patient in Europe for the first time.

At the time of writing, the OncoSil Medical share price is 7 cents, 66.67% higher than its previous close.

Though earlier today, it surged to an intraday high of 7.5 cents, representing a 78.6% gain.

Let’s take a closer look at today’s news from the medical device company.

What’s driving OncoSil’s stock higher?

The OncoSil Medical share price is launching higher on the news a European commercial patient has been treated with the company’s pancreatic cancer treatment device for the first time.

The OncoSil device is a targeted radioactive isotope. It works by being implanted into a pancreatic tumour via an endoscopic ultrasound.

The first European commercial procedure of its kind was performed at Madrid’s Hospital Universitario de Fuenlabrada.

Previously, COVID-19 had hampered the company’s ability to train hospitals on the device’s implantation. However, now restrictions have begun to ease, the company has trained 10 hospital sites in Spain.

The hospitals can now negotiate a budget for a certain number of treatments each year. To get their hands on the devices, hospitals must complete a formal tender process.

OncoSil Medical’s sales team is working with other trained hospitals through the tender process to allow better access to the treatment in various regions.

OncoSil Medical CEO and managing director Nigel Lange commented on today’s news:

We look forward to the OncoSil device becoming more accessible to patients throughout Spain and subsequently other European countries, to maximise the benefit from this novel treatment.

Overall, following our recent success in Germany, we expect the momentum of OncoSil device sales to continue improving over the course of the current year.

OncoSil Medical share price snapshot

This year has so far been good for the OncoSil Medical share price.

It has gained 40% since the start of 2022. However, it is 30% lower than it was this time last year.

The post The OncoSil Medical share price is booming 66%. Here’s why appeared first on The Motley Fool Australia.

Should you invest $1,000 in OncoSil Medical right now?

Before you consider OncoSil Medical, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and OncoSil Medical wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s